In conclusion, several cytokine-blockers (anti-IL-6, anti-IL-1, anti-TNF-α etc.)are currently under investigation for COVID-19 patients that are already in use or currently tested for the treatment of irAE [54]. The gene discussed is TNF; the disease is COVID-19.